Original Work

Factors associated with symptomatic dermographism: findings from the UCARE PREVALENCE-D study

656. Kulthanan, K., Bernstein, J. A., Rudenko, M., Salameh, P., Komoltri, C., Hameed, Z. A., Adışen, E., Al Abri, S., Al-Ahmad, M., Al Hinai, B., Allenova, A., Alshareef, S., Angkoolpakdeekul, N., Arnaout, R., Bartosińska, J., Cherrez-Ojeda, I., Chularojanamontri, L., Criado, P. R., Elsaeed, H., Criado, R. F. J., Farahat, A., Calle, C. A. G., Giménez-Arnau, […]

Factors associated with symptomatic dermographism: findings from the UCARE PREVALENCE-D study Read More »

Actual use of PROMs in asthma and rhinitis recommended by guidelines in clinical settings: PROMUSE respiratory study

655. Cherrez-Ojeda, I.+, Bousquet, J., Zuberbier, T., Calderon, J. C., Kolkhir, P., Allenova, A., Allenov, A., Tkachenko, S., Mihaltan, F., Ulmeanu, R., Al-Ahmad, M., Rodriguez-González, M., Wakida-Kusunoki, G., Ramon, G. D., Rukhadze, M., Larenas-Linnemann, D. E., Kosnik, M., Ivancevich, J. C., Ensina, L. F., Filho, N. A. R., Kvedariene, V., Chong-Neto, H. J., Tinoco, I.,

Actual use of PROMs in asthma and rhinitis recommended by guidelines in clinical settings: PROMUSE respiratory study Read More »

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

654. Maurer, M., Stobiecki, M., Valerieva, A., Hakl, R., Staevska, M. T., Bouillet, L., Du-Thanh, A., Kessel, A., Kiani-Alikhan, S., Magerl, M., Reshef, A., Baeza, M. L., Fain, O., Farkas, H., Greve, J., Guilarte, M., Jacobs, J. S., Li, H. H., Lleonart, R., Manning, M. E., Sussman, G. L., Anderson, J., Chapdelaine, H., Cohn, D.

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial. Read More »

The prevalence of symptomatic dermographism: results of the international UCARE PREVALENCE-D study

653. Kulthanan, K., Bernstein, J. A., Rudenko, M., Salameh, P., Komoltri, C., Adışen, E., Al Abri, S., Al-Ahmad, M., Al-Ahmed, N., Al Hinai, B., Allenova, A., Alshareef, S., Angkoolpakdeekul, N., Arnaout, R., Bartosińska, J., Cherrez-Ojeda, I., Chularojanamontri, L., Criado, P. R., Ensina, L. F., Criado, R. F. J., Calle, C. A. G., Giménez-Arnau, A. M.,

The prevalence of symptomatic dermographism: results of the international UCARE PREVALENCE-D study Read More »

Long-term safety and effectiveness of sebetralstat: interim analysis of KONFIDENT-S open-label extension

652. Farkas, H.+, Anderson, J., Bouillet, L., Caballero, T., Cancian, M., Craig, T., Fukunaga, A., Grivcheva-Panovska, V., Guilarte, M., Honda, D., Kanarek, H., Kiani-Alikhan, S., Kinaciyan, T., Leguevaques, D., Longhurst, H. J., Magerl, M., Manning, M. E., Martinez-Saguer, I., Melamed, I., O’Connor, M. E., Peter, J., Savic, S., Soteres, D. F., Staevska, M., Staubach, P.,

Long-term safety and effectiveness of sebetralstat: interim analysis of KONFIDENT-S open-label extension Read More »

The validity and reliability of a Thai version of the angioedema control test: which recall period is preferable?

651. Chularojanamontri, L., Kulthanan, K.+, Tuchinda, P., Rujitharanawong, C., Munprom, K., Pochanapan, O., Panjapakkul, W., Maurer, M., and Weller, K.: The validity and reliability of a Thai version of the angioedema control test: which recall period is preferable? Asian Pac. J. Allergy Immunol. 2025: 43; 504-512. IF: 2.10 o.651

The validity and reliability of a Thai version of the angioedema control test: which recall period is preferable? Read More »

Depletion of mast cells with barzolvolimab, an anti-KIT antibody, does not affect mast cell progenitors

650. Moñino-Romero, S., Mahnke, N. A., Terhorst-Molawi, D., Grekowitz, E. M., Kiefer, L. A., Alvarado, D., Metz, M., Siebenhaar, F., Scheffel, J.+, and Maurer, M.: Depletion of mast cells with barzolvolimab, an anti-KIT antibody, does not affect mast cell progenitors. J. Eur. Acad. Dermatol. Venereol. 2025: 39; e970-e972. IF: TBD (IF 2024: 8.00) o.650

Depletion of mast cells with barzolvolimab, an anti-KIT antibody, does not affect mast cell progenitors Read More »

Development and validation of a disease severity index for patients with cold urticaria

649. Altunergil, T.*, Pereira, M. P.*, Altrichter, S., Gutsche, A., Ahsan, D. M., Fox, L., Grekowitz, E., Bonnekoh, H., Weller, K., Maurer, M., Salameh, P., and Terhorst-Molawi, D.+: Development and validation of a disease severity index for patients with cold urticaria. J. Allergy Clin. Immunol. Pract. 2025: 2338-2348. IF: 9.20 o.649

Development and validation of a disease severity index for patients with cold urticaria Read More »

An overview on current practices regarding the diagnosis and management of chronic urticaria in pediatrics: an EAACI Task Force report

648. Arasi, S.+, Pite, H., Beken, B., Alvaro-Lozano, M., Brough, H., Caffarelli, C., Church, M. K., Flohr, C. C., Janmohamed, S. R., Konstantinou, G. N., Lau, S., Maurer, M., Mortz, C. G., Rutkowski, K., Staubach-Renz, P., van der Poel, L. A., Zuberbier, T., Weller, K., and Tsabouri, S.: An overview on current practices regarding the

An overview on current practices regarding the diagnosis and management of chronic urticaria in pediatrics: an EAACI Task Force report Read More »

CT-P39 compared with reference omalizumab in chronic spontaneous urticaria: results from a double-blind, randomized, active-controlled, phase 3 study

647. Saini, S. S., Maurer, M., Dytyatkovska, Y., Springer, E., Ratkova, M., Krusheva, B., Park, C. W., Pulka, G., Chelminska, M., Reich, A., Kim, S., Ahn, K., Kim, S., Lee, S., Ka, J., Kim, J., and Grattan, C.+: CT-P39 compared with reference omalizumab in chronic spontaneous urticaria: results from a double-blind, randomized, active-controlled, phase 3

CT-P39 compared with reference omalizumab in chronic spontaneous urticaria: results from a double-blind, randomized, active-controlled, phase 3 study Read More »